Agree Realty's ONC001 to be Featured at ASH Annual Meeting for Innovative Cancer Therapy
- OncoPrecision's ONC001 is set for an oral presentation at the ASH Annual Meeting in December 2025.
- ONC001 targets CD64, addressing monocyte-driven resistance in chronic myelomonocytic leukemia and acute myeloid leukemia.
- The therapy aims to transform treatment options for patients with resistant cases of CMML and AML.
Innovative Cancer Therapy ONC001 to Be Presented at ASH Annual Meeting
OncoPrecision Corporation announces that its groundbreaking development candidate, ONC001, has been selected for an oral presentation at the 67th Annual Meeting of the American Society of Hematology (ASH), scheduled for December 6-9, 2025, in Orlando, Florida. ONC001 is an antibody-drug conjugate (ADC) specifically designed to target CD64, a receptor frequently expressed in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) subtypes M4 and M5, particularly in patients with resistant cases. This innovative therapy emerges from OncoPrecision's proprietary discovery platform, which utilizes patient-derived biological data combined with AI-driven high-throughput screening to identify effective treatment modalities for aggressive blood cancers.
The development of ONC001 aims to address a significant challenge in the treatment of CMML and AML: monocyte-driven resistance. Preclinical studies led by Dr. Gastón Soria, OncoPrecision's Chief Scientific Officer, demonstrate ONC001's selective engagement with patient-derived cells, showcasing its robust efficacy against samples that are resistant to current therapies. The oral presentation at ASH will provide valuable insights into ONC001's unique mechanism of action and its potential to overcome treatment failures that have long plagued patients with these blood cancers. Tarek Zaki, the company’s CEO, emphasizes that ONC001's selection for an oral presentation underscores its promise as a novel approach to targeting resistance mechanisms in challenging leukemia cases.
Dr. Soria further elaborates on the importance of integrating patient biology insights into the development of ONC001. He highlights that, despite the recognition of CD64 as a biomarker for monocytic leukemia, there are currently no approved therapies that effectively target this receptor. This gap in treatment options positions ONC001 as a pioneering therapeutic candidate in the field, potentially transforming the landscape for patients suffering from CMML and AML. As OncoPrecision continues to advance ONC001 through IND-enabling studies, it reaffirms its commitment to innovation in cancer therapeutics, focusing on patient-centric strategies that address urgent medical needs.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

